Search results
Merck to buy eye-focused drug developer EyeBio for as much as $3 billion
Reuters via Yahoo Finance· 13 hours ago(Reuters) -Merck on Wednesday agreed to buy privately held biotech EyeBio for as much as $3 billion,...
Merck eyes purchase of ophthalmology company
WFMZ Eastern Pennsylvania and Western New Jersey· 2 hours agoTake Merck, for example. Its blockbuster cancer drug, Keytruda, is now the largest selling drug in the world. In the past few weeks, studies have shown...
Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio
The Wall Street Journal· 13 hours agoMerck, of Rahway, N.J., had sold some ophthalmology drugs, but it abandoned the market about a...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 13 hours agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.
Merck to Acquire EyeBio
Morningstar· 13 hours agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today ...
Merck to pay as much as $3 billion for eye treatment startup
Crain's New York Business· 10 hours agoWhile it raised its profit and sales forecast for the year on Keytruda sales, Merck has been on the...
Merck introduces sterility testing solution for pharma quality control
Pharmaceutical Technology via Yahoo Finance· 16 hours agoMerck KGaA, based in Darmstadt, Germany, has introduced the M-Trace Software & Mobile App, designed...
Vaccines Fast Facts – KION546
KION 46 Salinas· 6 hours agoThe Centers for Disease Control and Prevention (CDC) provides vaccine recommendations by age, as well as by disease. For more than 100 years, there has...
Merck Announces Third-Quarter 2024 Dividend
Morningstar· 1 day agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of ...
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
Barrons.com· 8 hours agoThe stumble in Moderna share price, Barron’s wrote Tuesday, comes as investors await updates on...
